Radioiodine Provides No Benefit After Thyroidectomy in Low-Risk Thyroid Cancer
Radioiodine after thyroidectomy did not improve outcomes in patients with low-risk thyroid cancer.
Radioiodine after thyroidectomy did not improve outcomes in patients with low-risk thyroid cancer.
When compared with chemotherapy or targeted therapy, peptide receptor radionuclide therapy significantly prolonged progression-free survival.
Researchers hypothesized that a rising number of thyroid cancer rates in adults with obesity in may also imply an increase in thyroid cancer rates in children.
The complete response rate was similar for patients who received selumetinib and those who received radioactive iodine alone.
The largest declines in incidence were seen for cervical, endocrine, and prostate cancers, as well as melanoma.
Elevated urinary 3MT levels were tied to worse event-free and overall survival.
Analysis of messenger RNA, microRNA, and protein-encoding genes may predict the risk of papillary thyroid cancer recurrence.
Apatinib improved progression-free survival regardless of baseline thyroglobulin levels.
Results from a phase 2 trial, if validated in a larger study, may be practice-changing, according to researchers.
¹⁷⁷Lu-Dotatate improved the median overall survival by 11.7 months.